Comprehensive Psychiatry
Volume 50, Issue 5 , Pages 453-462 , September 2009

Treatment response in psychotic patients classified according to social and clinical needs, drug side effects, and previous treatment; a method to identify functional remission

  • Malin Alenius

      Affiliations

    • Department of Pharmaceutical Biosciences, Uppsala University, 751 24 Uppsala, Sweden
    • Apoteket AB, 118 81 Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Apoteket AB, 118 81 Stockholm, Sweden. Tel.: +46 8 4661512.
    • ,
  • Margareta Hammarlund-Udenaes

      Affiliations

    • Department of Pharmaceutical Biosciences, Uppsala University, 751 24 Uppsala, Sweden
    • ,
  • Per Hartvig

      Affiliations

    • Department of Pharmacology and Pharmacotherapy, Section of Pharmacokinetics, University of Copenhagen, 2100 Copenhagen, Denmark
    • ,
  • Staffan Sundquist

      Affiliations

    • Apoteket Qulturum, 551 20 Jönköping, Sweden
    • ,
  • Leif Lindström

      Affiliations

    • Department of Neuroscience, Psychiatry, Uppsala University, 75185 Uppsala, Sweden

References 

  1. Harrow M, Sands JR, Silverstein ML, Goldberg JF. Course and outcome for schizophrenia versus other psychotic patients: a longitudinal study. Schizophr Bull. 1997;23:287–303
  2. Wieselgren IM, Lindstrom LH. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Acta Psychiatr Scand. 1996;93:9–19
  3. Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull. 1980;6:592–605
  4. Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull. 1980;6:606–618
  5. Modestin J, Huber A, Satirli E, Malti T, Hell D. Long-term course of schizophrenic illness: Bleuler's study reconsidered. Am J Psychiatry. 2003;160:2202–2208
  6. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, I: methodology, study sample, and overall status 32 years later. Am J Psychiatry. 1987;144:718–726
  7. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, II: long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry. 1987;144:727–735
  8. FDA . In: Clozaril. Prescribing Information. USA: Novartis Pharmaceuticals Corporation; 2004;p. 1–31http://www.fda.gov/medwatch/SAFETY/2005/MAY_PI/Clozaril_PI.pdf
  9. Meltzer HY. Defining treatment refractoriness in schizophrenia. Schizophr Bull. 1990;16:563–565
  10. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull. 1990;16:551–561
  11. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–796
  12. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159:255–262
  13. APA . Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry. 1997;154:1–63
  14. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441–449
  15. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand. 2006;113:91–95
  16. Peuskens J. The evolving definition of treatment resistance. J Clin Psychiatry. 1999;60(Suppl 12):4–8
  17. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:1409–1416
  18. Moller HJ. Problems associated with the classification and diagnosis of psychiatric disorders. World J Biol Psychiatry. 2005;6:45–56
  19. van Os J, Wright P, Murray R. Follow-up studies of schizophrenia I: natural history and non-psychopathological predictors of outcome. Eur Psychiatry. 1997;12:327–341
  20. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C. Important issues in the drug treatment of schizophrenia. Schizophr Bull. 1980;6:70–87
  21. Westermeyer JF, Harrow M. Prognosis and outcome using broad (DSM-II) and narrow (DSM-III) concepts of schizophrenia. Schizophr Bull. 1984;10:624–637
  22. Phelan M, Slade M, Thornicroft G, Dunn G, Holloway F, Wykes T, et al. The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness. Br J Psychiatry. 1995;167:589–595
  23. Hansson L, Bjorkman T, Svensson B. The assessment of needs in psychiatric patients. Interrater reliability of the Swedish version of the Camberwell Assessment of Needs instrument and results from a cross-sectional study. Acta Psychiatr Scand. 1995;92:285–293
  24. Arvidsson H. Test-retest reliability of the Camberwell Assessment of Need (CAN). Nord J Psychiatry. 2003;57:279–283
  25. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100
  26. Prieto L, Sacristan JA, Hormaechea JA, Casado A, Badia X, Gomez JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin. 2004;20:827–835
  27. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72
  28. de Hert M, Wampers M, Thys E, Wieselgren I, Lindström E, Peuskens J. Validation study of PECC (Psychosis Evaluation tool for Common use by Caregivers): interscale validity and inter-rater reliability. Int J Psych Clin Pract. 2002;6:135–140
  29. Lindström E, Ekselius L, Jedenius E, Almqvist A, Wieselgren I. A checklist for assessment of treatment in schizophrenic syndromes: interscale validity and inter-rater reliability. Prim Care Psychiatry. 1997;3:
  30. Borell P, Orhagen T, dÉlia G. Vad vet patienter med schizofreni om sin sjukdom?. Scand J Behav Ther. 1995;24:63–74
  31. Falloon I, Fadden G, Borell P, Kärräng L, Ivarsson B, Malm U. Integrerad psykiatri. Psykologia. 1997;1:ISBN 91-630-5438-5438
  32. Falloon IR. Expressed emotion: current status. Psychol Med. 1988;18:269–274
  33. National-Institue-of-Health . Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults—the evidence report. Obes Res. 1998;6:51S–209S
  34. Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther. 1995;274:921–927
  35. Movin-Osswald G, Hammarlund-Udenaes M, Von Bahr C, Eneroth P, Walton-Bowen K. Influence of the dosing interval on prolactin release after remoxipride. Br J Clin Pharmacol. 1995;39:503–510
  36. Movin-Osswald G, Karlsson P, Hammarlund-Udenaes M, Farde L. Influence of rate of administration of raclopride on akathisia and prolactin response. Psychopharmacology (Berl). 1994;114:248–256
  37. Friesen H, Erzin C, Godden J. In: Clinical endocrinology: a survey of current practice. New York: Appleton-Century-Crofts; 1977;p. 53–59Chapter 4
  38. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276
  39. Ericson B, Sandgren-Lundström G. Att använda Camberwell Assessment of Need inom Psykiatriska Rehabiliteringskliniken (PRE) i Jönköping-en pilotstudie (A pilot study on the use of the Camberwell Assessment of Need at the Department of Psychiatric Rehabilitation in Jönköping). Jönköping, Sweden: County Hospital of Ryhov, Department of Psychiatric Rehabilitation in Jönköping; 1995;
  40. Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry. 2000;15:220–226
  41. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65(Suppl 18):13–26
  42. Schwartz TL, Nihalani N, Jindal S, Virk S, Jones N. Psychiatric medication-induced obesity: a review. Obes Rev. 2004;5:115–121
  43. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand. 1999;100:3–16
  44. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358–363
  45. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097–1105
  46. Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab. 2007;33:169–175
  47. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724–763
  48. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry. 2002;14:163–173
  49. Pollock A, McLaren EH. Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol (Oxf). 1998;49:513–516
  50. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology. 2003;28(Suppl 2):69–82
  51. Weitzman ED. Circadian rhythms and episodic hormone secretion in man. Annu Rev Med. 1976;27:225–243
  52. Blair DT, Dauner A. Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs. Nurse Pract 1992;17:56, 62-54, 67.
  53. Burgyone K, Aduri K, Ananth J, Parameswaran S. The use of antiparkinsonian agents in the management of drug-induced extrapyramidal symptoms. Curr Pharm Des. 2004;10:2239–2248
  54. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191–208
  55. Gerlach J, Lublin H, Peacock L. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology. 1996;14:35S–39S
  56. Ossowska K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol J Pharmacol. 2002;54:299–312
  57. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158:1774–1782
  58. Antithrombotic-Trialists-Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86
  59. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98:746–750
  60. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383

 This research was funded by the National Corporation for Swedish Pharmacies (Apoteket AB, Stockholm, Sweden), which was the employer of Malin Alenius, Staffan Sundquist, and Per Hartvig at the time of the study. Apoteket AB had no further role in the study. All authors declare no conflict of interest that would inflict on the present study. The statistical analyses were performed by Malin Alenius, with support from Niclas Ericsson at the Uppsala Clinical Research Centre, Uppsala, Sweden.

PII: S0010-440X(08)00167-3

doi: 10.1016/j.comppsych.2008.11.001

Comprehensive Psychiatry
Volume 50, Issue 5 , Pages 453-462 , September 2009

Article Tools

* Image Usage & Resolution